Clinical Trial Detail

NCT ID NCT02721459
Title XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib + XL888

Age Groups: adult senior

Additional content available in CKB BOOST